Australia's most trusted
source of pharma news
Wednesday, 22 January 2025
Posted 17 January 2025 AM
New analysis shows the federal government spent just over $197 million on biosimilars in the 2023-24 financial year, a 13.5 per cent year-on-year increase.
Pharma in Focus compared biosimilar data from the 2022-23 FY and the 2023-24 FY PBS Expenditure and Prescriptions reports, which rank biosimilar brands by highest cost to government and excludes the Efficient Funding of Chemotherapy program.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.